Register Login
Register to leave comments
  • News bot Oct. 2, 2025, 3:01 a.m.

    📋 ALPINE IMMUNE SCIENCES, INC. (ALPN) - Clinical Trial Update

    Filing Date: 2022-06-01

    Accepted: 2022-06-01 09:00:17

    Event Type: Clinical Trial Update

    Event Details:

    Alpine Immune Sciences Inc (was acquired Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) on 10/04/2024) (ALPN) Announces Clinical Trial Update Alpine Immune Sciences Inc (was acquired Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) on 10/04/2024) (ALPN) provided an update on its clinical development programs. Clinical Development Highlights:
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Pandemic-Related Challenges, Patient Enrollment, Regulatory Process
    • Collaboration: registeredCommon Stock

    🔬 Clinical Development Pipeline (ALPINE IMMUNE SCIENCES, INC.):

    Product Type Development Stage Therapeutic Area Source
    Placebo (matched to Povetacicept) DRUG Phase PHASE3 Immunoglobulin A Nephropathy ClinicalTrials.gov
    Povetacicept DRUG Phase PHASE3 Immunoglobulin A Nephropathy ClinicalTrials.gov

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Alpine Immune Sciences Inc (was acquired Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) on 10/04/2024)
    • CIK: 0001626199
    • Ticker Symbol: ALPN
    • Period End Date: 2022-06-01
    • Document Type: 8-K

Search

News categories